Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
Executive Summary
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
You may also be interested in...
Novo Nordisk Pays $1.80bn To Buy Emisphere
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
Early Promise Of NextCure’s Novel IO Candidate Continues To Fade
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy
Novo Nordisk is paying $725m to acquire the VC-backed US biotech, Corvidia Therapeutics and its promising Phase II candidate, ziltivekimab, for chronic kidney disease, but further payments could total more than $2bn.